Skip to main content
. Author manuscript; available in PMC: 2019 Jul 11.
Published in final edited form as: JAMA Oncol. 2015 Nov;1(8):1087–1095. doi: 10.1001/jamaoncol.2015.2736

Figure 2.

Figure 2.

Comparison of progression-free survival (PFS). Medians: Arm A (median 5 cycles docetaxel given) 7.9 months versus Arm B (median 3 cycles given) 3.9 months (p = 0.09, 1-sided, meets predefined statistical goal), HR = 0.65 (95% CI: 0.34 – 1.14). Median potential follow-up 42.8 months.